Privately held Dyno Therapeutics Inc., an early stage biotech company applying artificial intelligence to gene therapy, entered a collaboration and license agreement with Spark Therapeutics Inc. that could bring Dyno milestone payments exceeding $1.8 billion. Read More
Cyclerion Therapeutics Inc.’s phase II blowup with sickle cell disease (SCD) candidate olinciguat ended its development, and attention turned to the Cambridge, Mass.-based firm’s earlier-stage effort with IW-6463, a drug in the same class for central nervous system (CNS) disorders. Read More
At the virtual Cell & Gene Meeting on the Mesa, panelists talked about the challenges and benefits of developing cell and gene therapies to treat chronic conditions. Read More
Rayzebio Inc. raised $45 million in a series A round to build a platform company focused on developing targeted radiopharmaceuticals for solid tumor indications. Read More
Tracking the pandemic in all its manifestations – from symptoms and spread, to viral genomics and repurposing drugs – has massively increased appreciation of the importance of real world data, with significant implications for the future of drug discovery and clinical development, the use of patient data and health care as a whole. Read More
Chinese biotech startup Affamed Therapeutics Ltd., funded by CBC Group, has merged with biopharmaceutical company Everinsight Therapeutics Inc., five days after it licensed in a dopamine agonist, KDT-3594, for Parkinson's disease from Japan’s Kissei Pharmaceutical Co. Ltd. Read More
Despite an NIH move to pause enrollment in a trial testing Eli Lilly and Co.'s COVID-19 antibody candidate, LY-CoV555, after a participant's unexplained illness, at least three other studies of the candidate remain underway, the company said Oct. 14. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amolyt, Anaptysbio, Auris, Azurrx, Basilea, Bone Therapeutics, Celldex, Cyclerion, Cytoagents, Evelo, Horizon, Ionis, Linnaeus, Mesoblast, Noxxon, Revance, Shasqi, TLC. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bayer, Biohaven, Direct, Enlivex, Harmony, Moderna, Orca, Redhill, Scynexis, Sorrento, Taysha Gene, Tevogen, Y-mabs. Read More
